Pareto analyst Dan Akschuti downgraded Calliditas Therapeutics to Hold from Buy with a SEK 208 price target after Asahi Kasei announced an agreement to acquire Calliditas.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- Calliditas Therapeutics downgraded to Hold from Buy at SEB Equities
- Wynn Resorts upgraded, PayPal initiated: Wall Street’s top analyst calls
- Calliditas Therapeutics downgraded to Neutral from Buy at Citi
- CHMP Endorses Calliditas’ Kinpeygo for IgAN
- Calliditas Therapeutics downgraded to Hold from Buy at Jefferies